ClinicalTrials.gg
Not yet recruitingNCT07939321TRACE-CancerUpdated Nov 16, 2026

Cardiovascular Risk and Outcomes in Patients With Cancer: The TRACE-Cancer Study

An observational study in Malignant Tumor, Cardiotoxicity and Cardio-oncology, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
50,000
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to investigate cardiovascular risks and long-term outcomes in adults with cancer in China. The main questions it aims to answer are:What is the risk of major adverse cardiovascular events (MACE) in patients with different types of cancer and anticancer treatments?Can clinical characteristics, cardiovascular assessments, and biomarkers help predict cardiovascular events and identify high-risk patients?This nationwide, multicenter study includes both retrospective and prospective cohorts. Researchers will collect clinical information from medical records and follow participants over time to assess cardiovascular health and outcomes.Participants in the prospective cohort will undergo cardiovascular assessments and follow-up as part of their clinical care. No experimental treatments will be assigned.

Read the detailed description

The TRACE-Cancer Study is a nationwide, multicenter, observational cohort study designed to evaluate cardiovascular risks and long-term outcomes in adults with cancer.The study includes a retrospective cohort of patients diagnosed between January 2018 and June 2026 and a prospective cohort enrolled from June 2026, with follow-up planned through December 2036.Clinical data will include cancer characteristics, anticancer treatments, cardiovascular risk factors, medical history, laboratory tests, cardiac imaging, and biomarkers. The primary outcome is major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, nonfatal stroke, and serious arrhythmias. Secondary outcomes include all-cause mortality, cancer-specific mortality, other cardiovascular complications, and changes in cardiac function.The study will also develop and validate cardiovascular risk prediction models to support early identification and prevention of cardiovascular complications in patients with cancer. All treatment decisions will follow routine clinical practice without study-assigned interventions.

02

Conditions studied

  • Malignant Tumor
  • Cardiotoxicity
  • Cardio-oncology

Keywords

  • Cardio-oncology
  • Cancer therapy
  • Cardiovascular risk stratification
  • Major adverse cardiovascular events
  • Risk prediction
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's planned enrollment of 50,000 is above the median of 200 across 2,641 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 315 studies on the registry; 88 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adults aged 18 years or older with pathologically or cytologically confirmed malignancies receiving cancer-related care at participating medical centers across China. The study includes two cohorts: a retrospective cohort of patients diagnosed and treated between January 2018 and June 2026, and a prospective cohort enrolling eligible patients from June 2026 onward. Participants will be recruited from general hospitals, cancer centers, and cardiovascular centers. All cancer types and stages are eligible, regardless of anticancer treatment or baseline cardiovascular status. Clinical information and long-term cardiovascular outcomes will be collected using standardized procedures. Biospecimen availability is not required for enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years or older.
  2. Patients with a or cytologically confirmed diagnosis of .
  3. Patients receiving cancer-related diagnosis, treatment, clinical assessment, or follow-up at participating centers.
  4. For the retrospective cohort, availability of traceable clinical records, including medical history, pathology reports, treatment information, or follow-up data.
  5. For the prospective cohort, provision of by the participant or legally authorized representative, in accordance with applicable ethical requirements.
  6. Availability of baseline clinical information and the ability to obtain follow-up information through clinical records, outpatient visits, hospitalization records, telephone contact, or other approved sources.

Exclusion criteria

Exclusion Criteria:

  1. Inability to confirm a diagnosis of .
  2. For the retrospective cohort, insufficient essential clinical information to establish baseline status or ascertain the primary outcome.
  3. For the prospective cohort, refusal to provide when required.
  4. Duplicate enrollment of the same participant at the same center; only the first eligible record will be retained.
  5. Other circumstances determined by the investigators to prevent appropriate participation or reliable follow-up.

Additional Consideration:

Patients will not be excluded based on cancer type, cancer stage, anticancer treatment modality, pre-existing cardiovascular conditions, comorbidities, or expected survival. The availability of biological specimens is not required for enrollment, and participants without available biospecimens will remain eligible for the clinical cohort.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
50,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Retrospective Cohort

    Adults aged 18 years or older with pathologically or cytologically confirmed malignancies who received medical care at participating centers between January 2018 and June 2026. Clinical characteristics, anticancer treatments, cardiovascular risk factors, and long-term outcomes will be collected retrospectively from existing medical records and available follow-up data.

  • Prospective Cohort

    Adults aged 18 years or older with pathologically or cytologically confirmed malignancies who are prospectively enrolled at participating centers beginning in June 2026. Clinical characteristics, anticancer treatments, cardiovascular assessments, and outcomes will be collected at baseline and during longitudinal follow-up through December 2036.

06

What researchers measure

Primary outcomes

  1. Time to First Major Adverse Cardiovascular Event (MACE)

    Time from baseline to the first occurrence of a major adverse cardiovascular event (MACE), defined as a composite of cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, nonfatal ischemic or hemorrhagic stroke, or serious arrhythmia. Serious arrhythmias include sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, arrhythmias requiring electrical cardioversion or defibrillation, severe bradyarrhythmias requiring permanent pacemaker implantation, and clinically significant new-onset atrial fibrillation or atrial flutter associated with hemodynamic compromise. The first qualifying event will be identified through medical records and follow-up information and adjudicated according to standardized diagnostic criteria.

    Time frame: From baseline to the first qualifying event or the end of follow-up, up to 10 years.

Secondary outcomes

  1. Time to All-Cause Mortality

    Time from baseline to death from any cause. Death events and dates will be identified using hospital medical records, available death registration information, and follow-up records. The cumulative incidence and time to all-cause mortality will be assessed during follow-up.

    Time frame: From baseline to death or the end of follow-up, up to 10 years.

  2. Time to Cancer-Specific Mortality

    Time from baseline to death attributed to the underlying malignancy or cancer-related complications. Cancer-specific mortality will be determined based on available medical records, documented causes of death, and follow-up information. Deaths from other causes will be treated as competing events in the analysis of cancer-specific mortality.

    Time frame: From baseline to cancer-related death or the end of follow-up, up to 10 years.

  3. Time to Cardiovascular Death

    Time from baseline to death attributed to cardiovascular causes, including fatal myocardial infarction, heart failure, stroke, sudden cardiac death, or other cardiovascular conditions. Cardiovascular death will be determined using available medical records, documented causes of death, and standardized adjudication criteria. Noncardiovascular deaths will be treated as competing events.

    Time frame: From baseline to cardiovascular death or the end of follow-up, up to 10 years.

  4. Time to First Nonfatal Myocardial Infarction

    Time from baseline to the first nonfatal myocardial infarction during follow-up. Myocardial infarction will be identified from clinical records and hospitalization data and confirmed according to standardized diagnostic criteria, including clinical presentation, cardiac troponin measurements, electrocardiographic findings, and available cardiac imaging or coronary angiographic evidence.

    Time frame: From baseline to the first nonfatal myocardial infarction or the end of follow-up, up to 10 years.

  5. Time to First Hospitalization for Heart Failure

    Time from baseline to the first hospitalization for newly diagnosed or worsening heart failure requiring inpatient treatment. Heart failure events will be identified through hospitalization records and confirmed using clinical symptoms, signs, cardiac imaging findings, laboratory results, and standardized diagnostic criteria.

    Time frame: From baseline to the first hospitalization for heart failure or the end of follow-up, up to 10 years.

  6. Time to First Nonfatal Stroke

    Time from baseline to the first nonfatal stroke, including ischemic and hemorrhagic stroke. Stroke events will be identified through clinical records, hospitalization data, and available neuroimaging findings and confirmed according to standardized diagnostic criteria.

    Time frame: From baseline to the first nonfatal stroke or the end of follow-up, up to 10 years.

  7. Time to First Serious Arrhythmia

    Time from baseline to the first occurrence of a serious arrhythmia, including sustained ventricular tachycardia, ventricular fibrillation, resuscitated cardiac arrest, arrhythmias requiring electrical cardioversion or defibrillation, severe bradyarrhythmias requiring permanent pacemaker implantation, and clinically significant new-onset atrial fibrillation or atrial flutter associated with hemodynamic compromise. Events will be identified through electrocardiograms, ambulatory electrocardiographic monitoring, implanted cardiac device records, hospitalization records, and clinical documentation.

    Time frame: From baseline to the first qualifying serious arrhythmia or the end of follow-up, up to 10 years.

Other outcomes

  1. Change in Plasma N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Concentration

    Change in plasma NT-proBNP concentration from baseline to follow-up, measured using validated clinical laboratory immunoassays and reported in pg/mL. Absolute changes in NT-proBNP concentration will be calculated among participants with available baseline and follow-up measurements. Exploratory analyses will examine the relationship between NT-proBNP levels and cardiovascular outcomes, particularly heart failure events, in participants with available clinical data and biospecimens.

    Time frame: Baseline and available follow-up assessments through 10 years.

  2. Change in Circulating Cardiac Troponin Concentration

    Change in circulating cardiac troponin concentration from baseline to follow-up, measured using validated clinical laboratory cardiac troponin assays and reported in assay-specific concentration units. Absolute changes will be evaluated among participants with available baseline and follow-up measurements. Exploratory analyses will investigate the relationship between circulating cardiac troponin concentrations and cardiovascular outcomes, particularly myocardial injury and major adverse cardiovascular events.

    Time frame: Baseline and available follow-up assessments through 10 years.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2036, 120 months later.

Of 1,098 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 120 months is above that.

Counting every sponsor, half of 1,246 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 16, 2026
StartEst.
Nov 11, 2026
Primary completionEst.
Dec 1, 2036
CompletionEst.
Dec 1, 2036
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07939321
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 11, 2026 (estimated)
Primary completion
Dec 1, 2036 (estimated)
Completion
Dec 1, 2036 (estimated)
Last update
Nov 16, 2026

Study contacts

Guoliang Li
Contact
guoliangli@xjtu.edu.cn
0086-2985323868
Shi Tao
Contact
shitao068@xjtu.edu.cn
0086-2985323865
Guoliang Li
principal investigator · First Affiliated Hospital Xi'an Jiaotong University
Tao Shi
principal investigator · First Affiliated Hospital Xi'an Jiaotong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion